The Cooper Companies/$COO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About The Cooper Companies

CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.

Ticker

$COO
Primary listing

Industry

Health Care Equipment & Supplies

Employees

16,000

ISIN

US2166485019

COO Metrics

BasicAdvanced
$15B
35.42
$2.07
0.99
-

What the Analysts think about COO

Analyst ratings (Buy, Hold, Sell) for The Cooper Companies stock.

Bulls say / Bears say

Cooper Companies reported a 15% increase in non-GAAP net income for its fiscal third quarter, indicating strong profitability growth. (nasdaq.com)
The company's CooperSurgical unit achieved a 9% year-over-year revenue increase, reflecting robust performance in its women's healthcare segment. (nasdaq.com)
Analysts have set an average price target of $110.25 for Cooper Companies, suggesting potential upside from current levels. (tickerreport.com)
Natixis reduced its holdings in Cooper Companies by 98.2% during the fourth quarter, indicating a significant divestment by a major institutional investor. (marketbeat.com)
Analysts have lowered their price targets for Cooper Companies, with Robert W. Baird reducing its target from $117.00 to $107.00, reflecting tempered expectations. (tickerreport.com)
The stock has experienced a year-to-date decline of 20.57%, indicating potential investor concerns about the company's near-term prospects. (cnbc.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jul 2025.

COO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

COO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $COO

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs